ArticleCancer research2015

Combining miR-10b-Targeted Nanotherapy with Low-Dose Doxorubicin Elicits Durable Regressions of Metastatic Breast Cancer.

Byunghee Yoo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.